Y-MABS THERAPEUTICS INC (YMAB) Stock Price, Quote, News and Overview
NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD
YMAB Quote, Performance and Key Statistics
5.72
-0.32 (-5.3%)
The current stock price of YMAB is 5.72 USD. In the past month the price decreased by -8.92%. In the past year, price decreased by -65.35%.
YMAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About YMAB
Company Profile
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2018-09-21. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Company Info
Y-MABS THERAPEUTICS INC
230 Park Avenue, Suite 3350
New York City NEW YORK 10169 US
CEO: Claus Juan Moller San Pedro
Employees: 100
Company Website: https://www.ymabs.com/
Investor Relations: https://ir.ymabs.com/
Phone: 12128479841
Y-MABS THERAPEUTICS INC / YMAB FAQ
What is the stock price of Y-MABS THERAPEUTICS INC today?
The current stock price of YMAB is 5.72 USD. The price decreased by -5.3% in the last trading session.
What is the ticker symbol for Y-MABS THERAPEUTICS INC stock?
The exchange symbol of Y-MABS THERAPEUTICS INC is YMAB and it is listed on the Nasdaq exchange.
On which exchange is YMAB stock listed?
YMAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Y-MABS THERAPEUTICS INC stock?
18 analysts have analysed YMAB and the average price target is 20.15 USD. This implies a price increase of 252.19% is expected in the next year compared to the current price of 5.72. Check the Y-MABS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Y-MABS THERAPEUTICS INC worth?
Y-MABS THERAPEUTICS INC (YMAB) has a market capitalization of 256.20M USD. This makes YMAB a Micro Cap stock.
How many employees does Y-MABS THERAPEUTICS INC have?
Y-MABS THERAPEUTICS INC (YMAB) currently has 100 employees.
What are the support and resistance levels for Y-MABS THERAPEUTICS INC (YMAB) stock?
Y-MABS THERAPEUTICS INC (YMAB) has a support level at 5.71 and a resistance level at 6.43. Check the full technical report for a detailed analysis of YMAB support and resistance levels.
Is Y-MABS THERAPEUTICS INC (YMAB) expected to grow?
The Revenue of Y-MABS THERAPEUTICS INC (YMAB) is expected to grow by 7.57% in the next year. Check the estimates tab for more information on the YMAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Y-MABS THERAPEUTICS INC (YMAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of YMAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of YMAB, evaluating the profitability, health, valuation and growth aspects
- Y-MABS THERAPEUTICS INC (YMAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Y-MABS THERAPEUTICS INC (YMAB) Sales and EPS estimates to see what analysts future expectations are.
- Y-MABS THERAPEUTICS INC (YMAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Y-MABS THERAPEUTICS INC (YMAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- Y-MABS THERAPEUTICS INC (YMAB) Stock Chart to make your own analysis
- Y-MABS THERAPEUTICS INC (YMAB) Latest news and press-releases to stay up to date.
Does Y-MABS THERAPEUTICS INC (YMAB) stock pay dividends?
YMAB does not pay a dividend.
When does Y-MABS THERAPEUTICS INC (YMAB) report earnings?
Y-MABS THERAPEUTICS INC (YMAB) will report earnings on 2025-05-05, after the market close.
What is the Price/Earnings (PE) ratio of Y-MABS THERAPEUTICS INC (YMAB)?
Y-MABS THERAPEUTICS INC (YMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.54).
What is the Short Interest ratio of Y-MABS THERAPEUTICS INC (YMAB) stock?
The outstanding short interest for Y-MABS THERAPEUTICS INC (YMAB) is 10.31% of its float. Check the ownership tab for more information on the YMAB short interest.
YMAB Technical Analysis
YMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to YMAB. No worries on liquidiy or solvency for YMAB as it has an excellent financial health rating, but there are worries on the profitability.
YMAB Financial Highlights
Over the last trailing twelve months YMAB reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS decreased by -22.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.74% | ||
| ROE | -25.82% | ||
| Debt/Equity | 0 |
YMAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to YMAB. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -28.83% and a revenue growth 7.57% for YMAB